Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease

2005 ◽  
Vol 57 (2) ◽  
pp. 267-279 ◽  
Author(s):  
Ulrich Klotz ◽  
Matthias Schwab
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Topical Delivery ◽  
Therapeutic Agents ◽  
Inflammatory Bowel

Interleukin-12 Antagonists as New Therapeutic Agents in Inflammatory Bowel Disease

Pathobiology ◽  
2002 ◽  
Vol 70 (3) ◽  
pp. 177-183 ◽  
Author(s):  
Carsten Schmidt ◽  
Thomas Marth ◽  
Bianca M. Wittig ◽  
Andreas Hombach ◽  
Hinrich Abken ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Therapeutic Agents ◽  
Interleukin 12 ◽  
Inflammatory Bowel

scholarly journals Drugs as causative agents and therapeutic agents in inflammatory bowel disease

2013 ◽  
Vol 3 (5) ◽  
pp. 289-296 ◽  
Author(s):  
Phani Krishna Kondamudi ◽  
Rajkumar Malayandi ◽  
Chandramohan Eaga ◽  
Deepika Aggarwal
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Therapeutic Agents ◽  
Causative Agents ◽  
Inflammatory Bowel

scholarly journals Sphingolipids as Mediators in the Crosstalk between Microbiota and Intestinal Cells: Implications for Inflammatory Bowel Disease

2016 ◽  
Vol 2016 ◽  
pp. 1-11 ◽  
Author(s):  
Phillips-Farfán Bryan ◽  
Carvajal Karla ◽  
Medina-Torres Edgar Alejandro ◽  
Espinosa-Padilla Sara Elva ◽  
Fabrias Gemma ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Immune Response ◽  
Immune System ◽  
Gut Microbiota ◽  
Bowel Disease ◽  
Therapeutic Agents ◽  
Intestinal Cells ◽  
Intestinal Immunity ◽  
Inflammatory Bowel

Inflammatory bowel disease (IBD) describes different illnesses characterized by chronic inflammation of the gastrointestinal tract. Although the pathogenic mechanisms leading to IBD are poorly understood, immune system disturbances likely underlie its development. Sphingolipids (SLs) have been identified as important players and promising therapeutic targets to control inflammation in IBD. Interestingly, it seems that microorganisms of the normal gut microbiota and probiotics are involved in sphingolipid function. However, there is a great need to investigate the role of SLs as intermediates in the crosstalk between intestinal immunity and microorganisms. This review focuses on recent investigations that describe some mechanisms involved in the regulation of cytokine profiles by SLs. We also describe the importance of gut microbiota in providing signaling molecules that favor the communication between resident bacteria and intestinal cells. This, in turn, modulates the immune response in the bowel and likely in other peripheral organs. The potential of SLs and gut microbiota as targets or therapeutic agents for IBD is also discussed.

Sign in / Sign up

Export Citation Format

Share Document